Abstract
Objectives We adopt a weighted variant burden score GenePy2.0 for the UK Biobank phase 2 cohort of inflammatory bowel disease (IBD), to explore potential genomic biomarkers underpinning IBD’s known associations.
Design Nucleating from IBD GWAS signals, we identified 794 GWAS loci, including target genes/LD-blocks (LDBs) based on linkage-disequilibrium (LD) and functional mapping. We calculated GenePy2.0–a burden score of target regions integrating variants with CADDPhred>15 weighted by deleteriousness and zygosity. Collating with other burden-based test, GenePy-based Mann-Whitney-U tests on cases/controls with varying extreme scores were used. Significance-levels and effect sizes were used for tuning the optimal GenePy thresholds for discriminating patients from controls. Individual’s binarized GenePy status (above or below threshold) of candidate regions, was subject to itemset association test via the sparse Apriori algorithm.
Results A tailored IBD cohort was curated (nCrohn’s_Disease(CD)=891, nUlcerative_Colitis(UC)=1409, nControls=60118). Analysing 885 unified target regions (794 GWAS loci and 104 monogenic genes with 13 overlaps), the GenePy approach detected statistical significance (permutation p<5.65×10-5) in 35 regions of CD and 25 of UC targets exerting risk and protective effects on the disease. Large effect sizes were observed, e.g. CYLD-AS1 (Mann-Whitney-□=0.89[CI:0.78-0.96]) in CD/controls with the top 1% highest scores of the gene. Itemset association learning further highlighted an intriguing signal whereby GenePy status of IL23R and NOD2 were mutually exclusive in CD but always co-occurring in controls.
Conclusion GenePy score per IBD patient detected ‘deleterious’ variation of large effect underpinning known IBD associations and proved itself a promising tool for genomic biomarker discovery.
What is already known on this topic Inflammatory bowel disease (IBD) is a genetically heterogeneous disease with both common polygenic, and rare monogenic, presentations. Previous studies have identified known genetic variants associated with disease.
What this study adds A genomic biomarker tool, tailored for large cohort, GenePy2.0 is developed. It’s rank-based test is more powerful than mutation-burden based test in validating known associations and finding new associations of IBD. We identified large risk and protective effects of ‘pathogenic genes/loci’ in IBD, including expanding previous associations to wider genomic regions.
How this study might affect research, practice or policy GenePy2.0 facilitates analysis of diseases with genetic heterogeneity and facilitates personalised genomic analysis on patients. The revealed genetic landscape of IBD captures both risk and protective effects of rare ‘pathogenic’ variants, alongside more common variation. This, could provide a fresh angle for future targeted therapies in specific groups of patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by AGENDA EPSRC funding on AI health research (EP/Y01720X/1) and was supported by the National Institute for Health Research (NIHR) Southampton Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
